Axial spondyloarthritis drugs market was valued at $4.8 billion in 2025 and is projected to reach $8.5 billion by 2035, growing at a CAGR of 6.0% during the forecast period 2026-2035, according to a new report by Orion Market Research. The axial spondyloarthritis drugs market is driven by rising disease prevalence, improved diagnostics, growing patient awareness, and increased access to advanced therapies. Among these factors, the adoption of biologic and targeted therapies such as TNF?? and IL?17 inhibitors remains the primary growth driver, offering better disease control, improved patient outcomes, and convenient administration options.
Browse the full report description of “Axial Spondyloarthritis Drugs Market Size, Share and Trends Analysis Report, By Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, Secukinumab, and Others), By Application (Clinic, Hospital, and Home Care), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/axial-spondyloarthritis-drugs-market
Rising Adoption of Biologic and Targeted Therapies Driving Market Growth
The increasing use of advanced biologic and targeted therapies is a key factor driving growth in the axial spondyloarthritis drugs market. Treatments such as biologic DMARDs, particularly TNF?? inhibitors and IL?17 inhibitors, have transformed disease management by helping to reduce inflammation, relieve pain, and slow disease progression more effectively than traditional therapies. Commonly used drugs, including secukinumab and ixekizumab, are increasingly preferred by healthcare providers due to their consistent effectiveness, manageable safety profiles, and overall patient tolerability.
In addition, innovations in drug administration, such as self-administered subcutaneous injections and user-friendly infusion devices, have made these therapies more accessible and convenient for patients. Growing awareness among both patients and physicians about the benefits of early and targeted treatment has further supported adoption. For instance, as per the British Society for Rheumatology (BSR) 2025 guideline, biologic and targeted therapies are recommended for patients with active axial spondyloarthritis who have not responded adequately to conventional treatment.
These factors collectively highlight how the increased adoption of advanced biologic and targeted therapies continues to be a primary driver of growth in the axial spondyloarthritis drugs market.
Recent Key Development in the Market
Market Coverage
Competitive Landscape – AbbVie Inc., Amgen Inc., Eli Lilly and Co., Johnson & Johnson Co. (Janssen Biotech, Inc.) and Pfizer Inc.
Key questions addressed by the report.
Global Axial Spondyloarthritis Drugs Market Report Segment
By Type
By Application
Global Axial Spondyloarthritis Drugs Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/axial-spondyloarthritis-drugs-market